Nebivolol Sandoz

Nebivolol, the active ingredient in Nebivolol Sandoz, is a beta blocker presented as a tablet for oral use. It selectively blocks β1‑adrenergic receptors and promotes nitric‑oxide mediated vasodilation, thereby lowering blood pressure and improving cardiac output in adults diagnosed with hypertension or chronic heart failure.

GNH USA supplies Nebivolol Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension. Heart failure: improves left ventricular ejection fraction and reduces hospitalization in patients with chronic heart failure.

Nebivolol may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially on standing. - Fatigue or tiredness. - Nausea or mild gastrointestinal upset. - Bradycardia: heart rate slower than normal. - Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia or heart block requiring medical attention. - Marked hypotension leading to fainting. - Acute bronchospasm in patients with reactive airway disease. - Allergic reactions such as rash, itching, or angioedema. - Worsening heart failure symptoms. - Liver enzyme elevations.

Before initiating therapy, several safety considerations are recommended.

Monitor blood pressure: ensure adequate control and avoid excessive drops. Assess cardiac function: evaluate heart rate and rhythm regularly. Use caution in severe hepatic impairment: dose adjustment may be required. Avoid abrupt discontinuation: taper under medical supervision to prevent rebound hypertension. Contraindicated in patients with severe bradycardia or second‑degree AV block. Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, affecting its safety and efficacy.

Major Interactions (Avoid): - Other beta‑blockers: additive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV block. - Strong CYP2D6 inhibitors (paroxetine, fluoxetine): elevated nebivolol plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, monitor electrolytes. - ACE inhibitors or ARBs: potential for excessive blood pressure reduction. - NSAIDs: may blunt antihypertensive response, check renal function.